HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

Pegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), ...

Gilead Sciences (GILD) stock in focus as cancer drug Trodelvy outperforms chemotherapy in a Phase 3 trial for advanced triple ...

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.

Now, Gilead Sciences has agreed to fork over $202 million to resolve allegations that it operated HIV speaker programs as a way to offer inducements for doctors to write prescriptions. In an ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Analysts expect Hookipa Pharma to post earnings of ($0.61) per share and revenue of $3.38 million for the quarter. Hookipa Pharma Trading Up 15.6 % HOOK opened at $1.48 on Wednesday.